ESR1 and breast carcinoma: In estrogen receptor (ER) positive breast cancers, accounting for 80% of all breast cancers, Her3 is mutated in up to 14% and its upregulation appears to be responsible for neuregulin-mediated resistance to Fulvestrant, an ER downregulator [37,38,39].